Cagrilintide: The Amylin Side of the GLP-1 Stack

If you've been watching the GLP-1 space, you've already seen the CagriSema headlines — Novo Nordisk combining semaglutide with this other peptide and getting weight loss numbers that make even tirzepatide blink. Cagrilintide is the "other peptide." And it's not a GLP-1 agonist at all.

Amylin is the pancreatic hormone insulin carpools with. Your pancreas makes both together, and amylin handles the parts of the satiety signal that insulin doesn't — slowing gastric emptying, suppressing glucagon, telling your brain the meal is over. Cagrilintide is a long-acting, albumin-bound version of amylin engineered to run on the same weekly schedule as semaglutide. When you stack them, the mechanisms don't overlap. They add.

What it is, in one paragraph

Cagrilintide is a 37-residue amylin analog with a C18 fatty-acid chain that binds serum albumin — the same half-life-extending trick semaglutide uses. It's a dual amylin and calcitonin receptor agonist, hitting hypothalamic and brainstem circuits that govern meal size and satiety. Once-weekly subcutaneous dosing. It's been studied in Phase 2 trials both as monotherapy (dose-dependent weight loss) and as CagriSema — cagrilintide plus semaglutide — where it produced meaningfully more weight loss than semaglutide alone.

Dosing: what people actually do

The published Phase 1/2 trial doses ran from 0.16 mg to 4.5 mg weekly. Community protocols tend to track the trial structure:

• Starting: 0.25 mg weekly
• Titration: step up by roughly 0.25–0.5 mg every 4 weeks as tolerated
• Target: 2.4 mg weekly (matching the semaglutide 2.4 mg dose)

In a CagriSema stack, both drugs are run at 2.4 mg weekly — the trial structure. Some people go higher on cagrilintide (up to 4.5 mg) if the semaglutide alone has plateaued, but that's past the well-documented window.

Titration matters. Amylin analogs produce more nausea and GI slowdown early in dosing than people expect. Jumping straight to target dose is the single fastest way to feel miserable and quit. Step up.

"Added cagri at 0.25 mg to my sema 1.0 mg protocol. Week one I barely noticed. Week four we were both at 2.4 and I'd dropped another 8 lbs that had been stuck for three months. The appetite suppression is just different from semaglutide — it's a full stomach feeling more than a 'not hungry' feeling." — forum user

What it pairs with

• Semaglutide. The canonical pairing. CagriSema is the protocol this compound is built for. Same weekly schedule, same sub-Q route, separate injections.
• Tirzepatide is a parallel approach rather than a stack — tirzepatide is already GLP-1 + GIP, and adding amylin on top pushes into territory without published trial data. Some people do it anyway. It's mechanistically reasonable but past the research evidence.
• Retatrutide same story — triple agonist, and adding cagrilintide is extrapolation territory.

The cleanest, evidence-supported play is plain CagriSema. Anything else is stacking beyond the data.

Red flags

Amylin analog side effects are, broadly, GI:

• Nausea — especially during titration, especially if you jump doses. Usually manageable with slower step-up and taking it the day before an easy day.
• Gastric slowdown. Gastric emptying slows on both sema and cagri. Stack both and the effect compounds. Smaller, slower meals. Lying down right after eating is rough.
• Hypoglycemia risk if stacked with insulin or sulfonylureas — coordinate with whoever's managing that rather than improvising.
• Gallbladder issues have been noted with rapid weight loss on any combination in this class. Not cagri-specific; dose-loss-rate specific.

What the long-term safety story looks like beyond a year or two is genuinely unknown — CagriSema Phase 3 data is still coming in as of 2026.

Honest limits

• Research-only status in the current supply chain. Cagrilintide does not have standalone FDA/EMA approval yet. Semaglutide does. That gap matters for sourcing.
• Published Phase 2 results are real; Phase 3 is what'll make or break the commercial product. The Phase 2 CagriSema numbers were extremely strong; we're in wait-for-confirmation territory for the bigger picture.
• The "beyond tirzepatide" weight loss claim depends heavily on which comparison arm you're looking at and at what time point. Don't let marketing telescope the full story.
• Injection-site rotation and cold-chain handling matter more with amylin analogs than with most peptides. Keep product cold, don't use the same spot twice, respect the expiration dates.

Where to go next

• Receptor pharmacology, the CagriSema trial arc, and the amylin analog family tree: Pepperpedia cagrilintide entry.
• Dose math, reconstitution, and titration planning: peppercalc.com.
• Real CagriSema cycle logs and comparison threads: Optimization forum.